Frontier Capital Management Co. LLC reduced its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 87.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 174,129 shares of the biopharmaceutical company’s stock after selling 1,243,107 shares during the quarter. Frontier Capital Management Co. LLC owned 0.14% of Celldex Therapeutics worth $498,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BB&T Securities LLC bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at about $117,000. Voya Investment Management LLC lifted its stake in shares of Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 7,499 shares during the last quarter. Overbrook Management Corp bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at about $139,000. Pacad Investment Ltd. bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at about $150,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at about $158,000. Hedge funds and other institutional investors own 55.98% of the company’s stock.

A number of research firms have recently weighed in on CLDX. HC Wainwright reissued a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Celldex Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.45.

Celldex Therapeutics, Inc. (CLDX) opened at $2.75 on Thursday. Celldex Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 45.56% and a negative net margin of 1,088.58%. The firm had revenue of $3.90 million for the quarter, compared to the consensus estimate of $1.30 million. During the same quarter in the prior year, the business earned ($0.29) EPS. The business’s revenue for the quarter was up 77.3% on a year-over-year basis. analysts forecast that Celldex Therapeutics, Inc. will post -1.03 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/09/frontier-capital-management-co-llc-cuts-stake-in-celldex-therapeutics-inc-cldx.html.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.